Cargando…

EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine

We report a case of secondary diffuse large B-cell lymphoma (DLBCL) after azacitidine (AZA) treatment in a 63-years-old man with myelodysplastic syndrome. The patient suffered from febrile neutropenia after 10 cycles of AZA treatment. Despite the performance of a whole-body CT scan, which showed a m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Naruko, Hiraga, Junji, Kato, Hiroki, Takagi, Yusuke, Ujihira, Nobuko, Narita, Michihiko, Kagami, Yoshitoyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519476/ https://www.ncbi.nlm.nih.gov/pubmed/28674363 http://dx.doi.org/10.2169/internalmedicine.56.7865

Ejemplares similares

Composite Lymphoma Comprising Extranodal NK/T-Cell Lymphoma and Diffuse Large B-Cell Lymphoma
por: Nagai, Shin, et al.
Publicado: (2018)

Prognostic Impact of a Body Mass Index Decrease during First Chemotherapy in Patients with Advanced Follicular Lymphoma
por: Ito, Makoto, et al.
Publicado: (2022)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012)

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer
por: Moriya, Keiichi, et al.
Publicado: (2020)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
por: Sato, Kazuya, et al.
Publicado: (2021)

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
por: Valencia, A, et al.
Publicado: (2014)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
por: Hashimoto, Miki, et al.
Publicado: (2019)

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes
por: Yang, Yanli, et al.
Publicado: (2020)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient
por: Yasuda, Tsukasa, et al.
Publicado: (2021)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain
por: Crespo, Carlos, et al.
Publicado: (2013)

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
por: Daitoku, Shinya, et al.
Publicado: (2018)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Somatic Hypermutations in the V(H) Segment of Immunoglobulin Genes of CDS‐positive Diffuse Large B‐Cell Lymphomas
por: Kume, Masaaki, et al.
Publicado: (1997)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

EBV-positive Reactive Hyperplasia Progressed into EBV-positive Diffuse Large B-cell Lymphoma of the Elderly over a 6-year Period
por: Kunitomi, Akane, et al.
Publicado: (2017)

Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
por: Lee, Jun Yong, et al.
Publicado: (2014)

An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum
por: Turan Erkek, Esra, et al.
Publicado: (2016)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Pericole, Fernando Vieira, et al.
Publicado: (2019)

Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
por: Makita, Shinichi, et al.
Publicado: (2017)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes
por: Baroud, Milad, et al.
Publicado: (2021)

Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome
por: Kitamura, Hiroaki, et al.
Publicado: (2021)

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients
por: Le Pannérer, Marguerite-Marie, et al.
Publicado: (2022)

The Characteristics of Epstein‐Barr Virus (EBV)‐positive Diffuse Large B‐Cell Lymphoma: Comparison between EBV(+) and EBV(‐) Cases in Japanese Population
por: Kuze, Tetuo, et al.
Publicado: (2000)

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma
por: Chabay, Paola
Publicado: (2021)

Molecular profiling of EBV associated diffuse large B-cell lymphoma
por: Frontzek, Fabian, et al.
Publicado: (2023)

Composite Lymphoma with Follicular Lymphoma Transformation to Clonally Related Epstein–Barr Virus (EBV) Positive Diffuse Large B-Cell Lymphoma and EBV-PositiveClassic Hodgkin Lymphoma
por: Ryder, Christopher B., et al.
Publicado: (2023)

Myelodysplastic syndrome with occult diffuse large B-cell lymphoma
por: Lee, Ja Young, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b9lafr02ke78b1lc661mb4a79f